British journal of haematology
Journal
Overview
publication venue for
-
CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm).
2007
-
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
2024
-
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
2024
-
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
2024
-
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
2024
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
2024
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
2024
-
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
2023
-
Natural history of blood pressure in sickle cell disease pregnancy.
2023
-
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.
2023
-
ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
2023
-
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
2023
-
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
2023
-
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials..
196.
2021
-
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens..
192.
2020
-
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma..
191.
2020
-
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study..
191.
2020
-
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting..
190.
2020
-
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma..
189.
2020
-
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy..
190.
2020
-
An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease..
189.
2020
-
Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP)..
189.
2020
-
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia..
188.
2019
-
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma..
186.
2019
-
Acute myeloid leukaemia niche regulates response to L-asparaginase..
186.
2019
-
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach..
185.
2019
-
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)..
185.
2019
-
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study..
185.
2018
-
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma..
184.
2018
-
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations..
184.
2018
-
Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)..
183.
2018
-
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells..
183.
2018
-
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma..
182.
2018
-
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials..
182.
2018
-
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study..
182.
2018
-
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome..
181.
2018
-
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network..
181.
2018
-
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications..
181.
2018
-
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients..
180.
2018
-
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R..
179.
2017
-
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials..
179.
2017
-
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma..
178.
2017
-
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib..
178.
2017
-
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study..
177.
2017
-
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study..
177.
2017
-
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1..
176.
2017
-
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106..
176.
2016
-
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era..
176.
2016
-
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia..
176.
2016
-
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study..
175.
2016
-
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation..
175.
2016
-
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia..
175.
2016
-
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704..
174.
2016
-
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay..
173.
2016
-
Central nervous system involvement in AIDS-related lymphomas..
173.
2016
-
Monoclonal gammopathy-associated pure red cell aplasia..
173.
2016
-
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation..
174.
2016
-
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months..
173.
2016
-
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study..
172.
2015
-
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial..
172.
2015
-
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era..
171.
2015
-
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center..
171.
2015
-
Human herpesvirus 6 infection in a bone marrow biopsy specimen after allogeneic stem cell transplantation..
171.
2015
-
Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke..
171.
2015
-
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402..
170.
2015
-
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States..
170.
2015
-
Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy..
170.
2015
-
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation..
168.
2014
-
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia..
168.
2014
-
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia..
168.
2014
-
In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia..
168.
2014
-
A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?.
167.
2014
-
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells..
166.
2014
-
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells..
166.
2014
-
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma..
166.
2014
-
Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia..
166.
2014
-
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era..
165.
2014
-
Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma..
164.
2013
-
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation..
164.
2013
-
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma..
163.
2013
-
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database..
163.
2013
-
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas..
163.
2013
-
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study..
162.
2013
-
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report..
162.
2013
-
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas..
162.
2013
-
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis..
162.
2013
-
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis..
161.
2013
-
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy..
161.
2013
-
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia..
161.
2013
-
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)..
160.
2012
-
Increased leucocyte apoptosis in transfused β-thalassaemia patients..
160.
2012
-
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP)..
160.
2012
-
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia..
158.
2012
-
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array..
156.
2011
-
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients..
155.
2011
-
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents..
155.
2011
-
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies..
154.
2011
-
Integrated profiling of diffuse large B-cell lymphoma with 7q gain..
153.
2011
-
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres..
153.
2011
-
Renal dysfunction in patients with thalassaemia..
153.
2011
-
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia..
153.
2011
-
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21..
151.
2010
-
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells..
151.
2010
-
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients..
150.
2010
-
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma..
149.
2010
-
Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura..
149.
2010
-
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging..
148.
2010
-
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura..
148.
2009
-
Genome wide DNA-profiling of HIV-related B-cell lymphomas..
148.
2009
-
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma..
146.
2009
-
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America..
146.
2009
-
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma..
146.
2009
-
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma..
146.
2009
-
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma..
146.
2009
-
Risk of non-Hodgkin lymphoma in association with germline variation in complement genes..
145.
2009
-
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial..
145.
2009
-
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials..
144.
2008
-
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma..
143.
2008
-
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation..
143.
2008
-
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma..
143.
2008
-
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma..
143.
2008
-
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone..
143.
2008
-
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma..
143.
2008
-
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation..
142.
2008
-
The effect of anti-CD40 ligand in immune thrombocytopenic purpura..
141.
2008
-
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells..
140.
2008
-
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma..
139.
2007
-
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial..
139.
2007
-
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy..
138.
2007
-
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator..
138.
2007
-
Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load..
138.
2007
-
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP..
138.
2007
-
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia..
137.
2007
-
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis..
137.
2007
-
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia..
137.
2007
-
Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate..
136.
2006
-
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time..
135.
2006
-
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?.
134.
2006
-
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma..
133.
2006
-
Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21)..
133.
2006
-
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma..
132.
2006
-
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999..
130.
2005
-
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease..
130.
2005
-
Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia..
130.
2005
-
Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas..
129.
2005
-
Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease..
127.
2004
-
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma..
127.
2004
-
Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists..
127.
2004
-
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease..
125.
2004
-
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants..
125.
2004
-
t(11;18)(q21;q21) of mucosa-associated lymphoid tissue lymphoma results from illegitimate non-homologous end joining following double strand breaks..
125.
2004
-
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura..
125.
2004
-
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease..
124.
2004
-
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms..
124.
2004
-
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades..
124.
2004
-
Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy..
123.
2003
-
Beta7E-beta132K salt bridge and sickle haemoglobin stability and conformation..
122.
2003
-
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation..
122.
2003
-
High frequency of t(11;18) in gastric mucosa-associated lymphoid tissue lymphomas in Taiwan, including one patient with high-grade transformation..
120.
2003
-
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission..
119.
2002
-
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units..
119.
2002
-
High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura..
118.
2002
-
Beta(2)-microglobulin as a negative growth regulator of myeloma cells..
118.
2002
-
Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults..
118.
2002
-
Optimizing dendritic cell-based immunotherapy in multiple myeloma..
117.
2002
-
Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia..
117.
2002
-
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity..
116.
2002
-
beta-Spectrin S(ta) Bárbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism..
115.
2001
-
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura..
112.
2001
-
Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway..
112.
2001
-
Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma..
112.
2001
-
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia..
111.
2000
-
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma..
109.
2000
-
Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia..
108.
2000
-
Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc..
107.
1999
-
Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells..
100.
1998
-
Expression of interleukin-5 by human bone marrow microvascular endothelial cells: implications for the regulation of eosinophilopoiesis in vivo..
99.
1997
-
Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy..
99.
1997
-
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease..
97.
1997
-
Collection of peripheral blood stem cells from normal donors 60 years of age or older..
97.
1997
-
Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets..
96.
1997
-
Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation..
96.
1997
-
Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome..
93.
1996
-
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients..
92.
1996
-
Serum levels of GM-CSF are elevated in patients with thrombocytopenia..
92.
1996
-
Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma..
89.
1995
-
Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests..
89.
1995
-
Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group..
87.
1994
-
High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer..
83.
1993
-
18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance..
72.
1989
-
In vitro interferon-gamma production by cultured T-cells in severe aplastic anaemia: correlation with granulomonopoietic inhibition in patients who respond to anti-thymocyte globulin..
69.
1988
-
In vitro multimerization of human von Willebrand factor from its subunits..
67.
1987
-
DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation..
60.
1985
-
Disproportionate lymphoid cell subsets in thalassaemia major: the relative contributions of transfusion and splenectomy..
59.
1985
-
Serum transcobalamin levels as an early indicator of bone marrow engraftment following transplantation..
55.
1983
-
ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation..
54.
1983
-
SV40 T-antigen expression in acute non-lymphocytic leukaemia..
43.
1979
-
Association of IgA multiple myeloma with pre-existing disease..
41.
1979
-
Myosin in cultured human endothelial cells..
35.
1977
-
Platelet dysfunction in vincristine treated patients..
32.
1976
-
The effect of platelet membrane antibodies on aggregation and release..
28.
1974
-
Immunological studies of proteins associated with the subcellular fractions of thrombasthenic and afibrinogenaemic platelets..
15.
1968
-
Familial thrombocythaemia - a distinct entity from essential thrombocythaemia..
194.
2021
-
Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients..
190.
2020
-
Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children..
189.
2020
-
A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathy..
189.
2020
-
Kidney transplantation in AL Amyloidosis: is it time to maximize access?.
188.
2019
-
FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency..
186.
2019
-
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia..
186.
2019
-
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor..
185.
2018
-
Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms..
185.
2018
-
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study..
182.
2017
-
The safety of chronic antithrombotic therapy in patients with factor XI deficiency..
179.
2016
-
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study..
178.
2016
-
Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor..
173.
2015
-
A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma..
168.
2014
-
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study..
162.
2013
-
Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up..
162.
2013
-
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists..
158.
2012
-
Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis..
155.
2011
-
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera..
130.
2005
-
Immune thrombocytopenic purpura: investigation of the role of cytomegalovirus infection..
126.
2004
-
Endothelial cell activation and apoptosis in the thrombotic microangiopathies..
125.
2004
-
Maternal IVIG in neonatal alloimmune thrombocytopenia..
98.
1997
-
Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
2023
-
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.
2021
-
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.
2018
-
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.
2017
-
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
2015
-
Unreliable oral glucose tolerance test and haemoglobin A1C in beta thalassaemia major--a case for continuous glucose monitoring?
2013
-
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura.
2012
-
Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease.
2011
-
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.
2008
-
Immune thrombocytopenia: a need for assisted suicide..
176.
2016
-
Haemophilia: factoring in new therapies.
2021
-
Checkpoint inhibitors in AML: are we there yet?
2019
-
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
2015
-
Genetic strategies for the treatment of sickle cell anaemia.
2011
-
Refractory immune thrombocytopenic purpura: current strategies for investigation and management.
2008
-
Inhibitor development in haemophilia B: an orphan disease in need of attention.
2007
-
Advances in the management of alloimmune thrombocytopenia.
2007
-
The pathogenesis of immune thrombocytopaenic purpura.
2006
-
Molecular mechanisms of fibrinolysis.
2005
-
Bone marrow histopathology in peripheral T-cell lymphomas.
2004
-
Angioimmunoblastic T-cell lymphoma.
2003
-
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
2000
-
Genetic treatment of the haemoglobinopathies: recombinations and new combinations.
1997
-
The power and perils of large language models in haematology.
2024
-
Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia.
2023
-
Thalassaemia-A global view.
2023
-
Therapeutic use of regulatory T cells for graft-versus-host disease.
2019
-
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
2018
-
Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
2016
-
Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.
2015
-
Sickle cell disease: time for a closer look at treatment options?
2013
-
Coagulation and metastasis: what does the experimental literature tell us?
2013
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)